Elicio Therapeutics, Inc. Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent
Elicio Therapeutics, Inc. (ELTX) had Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent of $0 as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Compensation Related Costs
us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent · last filed 2024-03-29
- 2023-12-31: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $0.00.
- 2023-09-30: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $0.00.
- 2023-06-30: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $46.00K.
- 2022-12-31: Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent $92.00K.
| Period end | Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 |
| 2023-06-30 | $46.00K 10-Q · filed 2023-08-14 |
| 2022-12-31 | $92.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |